DR. J. JAMES FROST
Dr. J. James Frost, President of BioMolecular Imaging, provides expert advice on anatomic & molecular imaging from entire organ systems to small molecules, peptides & antibodies. His expertise spans early and late-stage clinical trials, data analysis, and expert image reads as well as liaisons with the FDA, CROs and academic imaging sites.
Dr. Frost is an M.D. radiologist with a Ph.D. degree in nuclear and radiochemistry. He also holds an M.B.A. degree from Johns Hopkins University. He is Professor Emeritus of radiology and neuroscience at the Johns Hopkins University School of Medicine.
Cancer investigator
Molecular imaging Specialist
Clinical trials reader
Clinical radiology and nuclear medicine
Consulting for pharma, CROs, diagnostics, and biotech
FEATURED CANCER-PHYSICS TRILOGY
Dr. J. James Frost highlights the discussion of intelligence as applied to cancer; computation and its limits and develops a new approach to advanced personalized oncology where elucidation of the patient's intrinsic cancer computational machine and its gameplay strategies, coupled to recent developments in AI human gameplay, including bluffing and deception, can lead to vastly improved strategies for the oncologist to defeat the patient's cancer.
"Is there a parallel to be drawn between bluffing in poker and bluffing in cancer’s game with the oncologist?"
Symmetry and symmetry breaking principles are applied to cancer, categorizing them into combinatorial, geometric, and functional aspects, exploring their relevance to features like EMT, tumor heterogeneity, and functional interaction networks, offering a novel perspective that may contribute to understanding cancer's origin, spread, treatment, and resistance.
Cancer is viewed as an intelligent system with collaborative and computing cells, highlighting the limitations of current research and treatment, advocating for a new paradigm, and exploring the application of computational concepts to describe cancer's intelligent features, leading to implications for future research.
I wrote the lead chapter, "What Cancer Is" exploring novel therapeutic insights and a deeper understanding of cancer's fundamental nature for the book, Cancer, Complexity, Computation, which offers a diverse compendium of interdisciplinary perspectives on cancer from top experts in oncology, complexity theory, mathematics, and computer science.
BIOMOLECULAR IMAGING
Provides expert advice on anatomic & molecular imaging from entire organ systems to small molecules, peptides & antibodies. His expertise spans early and late-stage clinical trials, data analysis, and expert image reads as well as liaisons with the FDA, CROs and academic imaging sites.
CONSULTING PROJECTS
CLINICAL TRIALS
Served as the internal clinical imaging expert for a large public biotech company in a FIH clinical trial for a novel cancer imaging radiolabeled peptide
CORPORATE
Chaired an advisory board meeting for a large US corporation for post approval rollout and a new CNS probe-specific imaging workstation.
IMAGING PARTNERSHIPS
Evaluated U.S. imaging CRO’s for a large international CRO during a multi-month project to select an imaging CRO partner
PUBLIC BIOTECH
Developed an imaging strategy, created imaging protocols, and identified preclinical/clinical imaging sites for an antibody cancer therapeutic program of a public biotech corporation
LARGE PHARMA
Developed and evaluated post approval strategies and phase IV imaging opportunities for a large pharma CNS diagnostic imaging agent
FUNDING
Provided due diligence guidance to a venture capital company in consideration of funding a preclinical CRO start-up. Identified and interfaced with additional VC’s for syndication funding
DRUG CANDIDATES
Advised a large pharma company in the development of an imaging strategy and protocol to examine CNS side effects of a new drug candidate
BUSINESS DEVELOPMENT
Developed a business plan and scientific strategy for a diagnostic cancer imaging start-up company
STRATEGIC PLANNING
Developed an imaging strategy and experimental design for a novel organ imaging need of a small cap pharmaceutical company
